Adverum Biotechnologies, Inc. (ADVM)

Biological Products, (No Diagnostic Substances) · market cap $96M · as of 2026-07-14

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Adverum Biotechnologies (ADVM) is a ~$96M market cap clinical-stage gene therapy company focused on ocular diseases. Its lead program is an intravitreal aflibercept gene therapy (ADVM-022) in Phase 3 for neovascular AMD, with a key readout estimated around December 2026. A secondary asset targeting diabetic macular edema is in Phase 2.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
6E11 vg/eye of ADVM-022	Phase 2	Diabetic Macular Edema

Price & technical context

3-month

+31.7%

6-month

+56.3%

12-month

-23.4%

52-wk range

$2.05–$5.93

vs 50-day MA

-1.1%

vs 200-day MA

+25.4%

Realized vol

86.6%

Max drawdown

-92.7%

Daily closes through 2025-12-09. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ADVM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.